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is by the restoration of bloodﬂow [1]. The body achieves this by the pro-
cess of angiogenesis. Ischaemic tissue releases angiogenic growth fac-
tors such as Vascular Endothelial Growth Factor (VEGF), Fibroblast
Growth Factor and angiopoietins to stimulate the co-ordinated
sprouting of new vessels from pre-existing blood vessels [2]. New
methods of stimulating angiogenesis are eagerly sought as treatments
for various diseases that involve ischaemia, including ischaemic heart
disease, ischaemic stroke, peripheral artery disease and wound healing,
but to date, efforts to develop a drug to stimulate neovascularization, for
example via the administration of VEGF or other growth factors, have
seen limited success [2]. Although VEGF stimulates vessel growth in an-
imal models, it also increases vascular permeability, which can be detri-
mental [2]. Itmay be that a different approach is needed. In this regard, a
new study by Xu et al. in this issue of EBioMedicine shows that the pro-
tein FAM3A stimulates angiogenesis in a mouse hind limb ischaemia
model, via an intriguing signalling pathway that originates in the mito-
chondria, and leads to an increase in local VEGF production via
purinergic signalling [3].
FAM3A is one of a family of four, cytokine-like proteins including
FAM3B, FAM3C, and FAM3D [4]. While FAM3A and FAM3B are ubiqui-
tously expressed, FAM3B and FAM3D have more localized expression
in the pancreas and placenta, respectively [4]. FAM3A is highly
expressed in vascular endothelium, but is also present in other cell
types. Expression of FAM3A has previously been detected in the tunica
media of rat arteries, where it promotes neointima formation after bal-
loon injury via the PI3K/AKT pathway [5]. Curiously, despite FAM3A
containing a predicted signal peptide for cellular secretion, it is mainly
found localized to mitochondria within cells [5], where changes in its
expression levels modulate mitochondrial respiratory activity [5].
When overexpressed, it enhances ATP production, contributing to an
overall increase in the cellular release of ATP. This extracellular ATP
then binds and stimulates purinergic receptors such as P2Y1, leading
to the activation of downstream, protein-kinase signalling pathways in-
cluding PI3K/AKT [5].DOI of original article: https://doi.org/10.1016/j.ebiom.2019.03.038.
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lism [6]. Interestingly, a marked reduction of FAM3A expression was
found in the livers of diabetic mice [6]. Hepatic overexpression of
FAM3A was able to attenuate different measures of diabetes by activat-
ing the PI3K-AKT signalling pathway [6]. In a pathway similar to that de-
scribed above, an increase in mitochondrial ATP production in
hepatocytes overexpressing FAM3A led to an increase in the synthesis
and release of extracellular ATP, thereby activating PI3K/AKT signalling
via P2 ATP receptors in the plasmamembrane [6]. Since insulin also acts
via PI3K/AKT, these results demonstrate a potentially important insulin-
sensitizing role for FAM3A in the liver [6]. Conversely, obesity may
contribute to the progression of type 2 diabetes by repressing FAM3A-
ATP-AKT signalling [7].
Returning to the new publication by Xu et al., the localization of
FAM3A in endothelial cells was ﬁrst conﬁrmed as being mitochon-
drial by immunostaining and subcellular fractionation [3]. Despite
the fact that endothelial cells are usually primarily glycolytic, they
contain mitochondria which have important functions in various as-
pects of cell physiology, from the regulation of Ca2+ signalling dy-
namics, to the control of cell death pathways such as apoptosis [8].
When endothelial FAM3A expression was increased, this caused an
increase in ATP production and secretion, which was then able to
bind to and activate plasma membrane P2 receptors, causing an in-
crease in cytosolic Ca2+ levels [3]. This stimulated the transcription
of VEGF-A, leading to an increase in endothelial angiogenesis [3].
An increase in the expression of FAM3A was found to promote endo-
thelial tube formation, proliferation and migration, and also im-
proved blood perfusion and capillary density in a mouse, hind limb
ischaemia model [3]. Silencing of FAM3A had the opposite effect, de-
creasing mitochondrial respiration and ATP production and
impairing angiogenesis [3]. Together, these data show that endothe-
lial FAM3A positively regulates post-ischaemic angiogenesis [3].
Since it appears to work via an autocrine stimulation of endogenous
VEGF release, it may overcome some of the problems seen with the
stimulation of angiogenesis by the addition of exogenous VEGF.
How FAM3A modulates mitochondrial respiration remains an im-
portant, but unanswered question. Interestingly, endothelial mitochon-
dria have also been implicated in the anti-ischaemic signalling pathway
of other proangiogenic ligands such as SDF-1α [9]. Since mitochondrial
dynamics and morphology is affected by mitochondrial respiration, it
would be interesting to lookmore closely atmitochondrial morphology
in cells with altered expression of FAM3A.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2 S.M. Davidson / EBioMedicine xxx (2019) xxxIf there is prospect for FAM3A regulation as a future pro-angiogenic
therapy in patients, a simple and convenient means of increasing
FAM3A expression without gene therapy would be preferable. Interest-
ingly, rosiglitazone, an agonist of peroxisome proliferator-activated
receptor gamma (PPARγ), has been shown to upregulate FAM3A
expression in mouse hepatocytes [10]. Via this mechanism, in vivo
administration of rosiglitazone increases FAM3A and, consequently,
AKT activity, in liver cells [10]. However, it could be problematic if
rosiglitazone increased FAM3A expression in all cells, since, as men-
tioned, its expression in smoothmuscle can lead to neointima formation
[5]. In any case, rosiglitazone is not a suitable drug itself, as it was
withdrawn from the market due to cardiotoxicity. Future studies are
also necessary to conﬁrm that FAM3A upregulation is effective as a
pro-angiogenic therapy in animal models with co-morbidities such as
diabetes and obesity, since these often impair angiogenic pathways in
patients [2].
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